



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/846,512

05/01/2001

Rachel A. Meyers

10448-046002 /
MPI2000-18

5523

7590

11/27/2001

LOUIS MYERS
FISH & RICHARDSON P.C.
225 Franklin Street
Boston, MA 02110-2804

EXAMINER

DAVIS, NATALIE A

ART UNIT

PAPER NUMBER

1642

DATE MAILED: 11/27/2001

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/846,512

Applicant(s)

MEYERS ET AL.

Examiner

Natalie A. Davis

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 August 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-53 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-53 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-7, 12, and 18, drawn to a nucleic acid molecule, vector, host cell, and method of making a protein, classified in class 536, subclass 23.1.
 - II. Claims 8-10 and 15, drawn to a polypeptide and kit, classified in class 530, subclass 350.
 - III. Claim 11, drawn to an antibody, classified in class 530, subclass 387.1.
 - IV. Claims 13-14, drawn to a method of detecting a polypeptide, classified in class 435, subclass 7.1.
 - V. Claims 16-17, drawn to a method of detecting a nucleic acid molecule, classified in class 435, subclass 6.
 - VI. Claims 19-20, drawn to a method of identifying a compound that binds to a polypeptide, classified in class 435, subclass 4.
 - VII. Claim 21- and 23-31, drawn to a method of modulating the activity a polypeptide of claim 8 or expression and inhibiting the proliferation or inducing the killing of a 14094-expressing hyperproliferative cell, classified in class 424, subclass 184.1.
 - VIII. Claims 22, drawn to a method of identifying a compound that modulates polypeptide activity, classified in class 435, subclass 4.
 - IX. Claims 32 and 34-43, drawn to a method of treating or preventing a cellular proliferation disorder in a subject, classified in class 514, subclass 2.
 - X. Claim 33, drawn to a method of treating or preventing a cellular proliferation disorder in a subject, classified in class 514, subclass 44.
 - XI. Claims 52-53, drawn to a method of evaluating the efficacy of a treatment of a proliferation disorder in a subject, classified in class 424, subclass 9.1.
- A. In the event applicant elects Group I or II, applicant is required to elect a single species of nucleic acid sequence, comprising:
Species A, drawn to SEQ ID NO: 1

Art Unit: 1642

Species B, drawn to SEQ ID NO: 2

Species C, drawn to SEQ ID NO: 3

Species D, drawn to SEQ ID NO: 11

Species E, drawn to SEQ ID NO: 12

Species F, drawn to SEQ ID NO: 13

Species A-F are patentably distinct based on structural and functional differences and mode of action, as species may target different receptors.

B. In the event applicant elects Group VII, claims 21 and 23-31, applicant is required to elect a single species of compound, comprising:

Species G, drawn to a peptide and phosphopeptide

Species H, drawn to small organic molecule

Species I, drawn to antibody

Species G-I are patentably distinct based on structural and functional differences and mode of action, as species may target different receptors.

The inventions are distinct, each from the other because of the following reasons:

2. The Inventions of Groups I-III (products) and IV-VIII (methods) are related as products and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products of Groups I-III may be used for a number of different processes that are very much unrelated. For example, the antibody of Group III may not only be used in the method of Group IV, but may also be used for immunopurification. Likewise, the protein of Group II may be used for affinity purification of antibodies and not just in the methods of Groups VI-VIII and IX. Furthermore, the invention of Group I, may be used to make a protein and not only in the method of Group X.

Art Unit: 1642


3. The products of Groups I-III are drawn to structurally and functionally different molecules with different immunological properties, each invention requires different reagents and steps to make and characterize it.
4. The methods of Groups IV-XI relate to methods but each method differs in method steps, modes of operation, reagents needed and serve different endpoints and effects.
5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, divergent subject matter, and require different search strategies, restriction for examination purposes as indicated is proper.
6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Natalie A. Davis whose telephone number is 703-308-6410. The examiner can normally be reached on M-F 8-5:30 (every other Friday off).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4315 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Natalie A. Davis
November 5, 2001


GEEETHA P. BANSAL
PRIMARY EXAMINER